Company / Interest Expense
ImmunityBio, Inc. Interest Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$60.9M
FY2025
5-year range
$5.9M / $128.8M
FY2021-FY2025
Trend
-46.9%
vs FY2024
Sector context
#11 of 44
Health Care
What the data says
ImmunityBio, Inc.'s interest expense of $61M is higher than 75% of companies in the Health Care sector (FY2025). Interest Expense has fluctuated over the past 9 years, ranging from $0 in FY2017 to $129M in FY2023.
Based on SEC 10-K filings.
$61M in FY2025 with a 5-year CAGR of +46.3%. Top quartile in the Health Care sector.
Improved from $129M to $61M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -1.4%
- 5-Year CAGR
- +46.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 44This company $60.9M Sector average $291.0M
▼
-79.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +46.3%, indicating consistent growth.
- In FY2025, interest expense decreased 46.9% year-over-year.
- Ranks #11 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $60.9M | -46.9% |
| FY2024 | $114.6M | -11.1% |
| FY2023 | $128.8M | +102.9% |
| FY2022 | $63.5M | +972.9% |
| FY2021 | $5.9M | -34.8% |
| FY2020 | $9.1M | +53.3% |
| FY2019 | $5.9M | - |
| FY2018 | - | - |
| FY2017 | $0 | -100.0% |
| FY2016 | $471.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026